Co-management Reference

Atropine Awareness Tool

Compare atropine concentrations (0.01%, 0.05%, 0.1%) for myopia control co-management — trial efficacy, side-effect profiles, and follow-up schedules based on ATOM1, ATOM2, and LAMP evidence.

Last updated: April 2026

Singapore scope of practice: Atropine is a Schedule 1 prescription medication. Singapore optometrists cannot prescribe or dispense atropine. This tool is for co-management awareness only — to help you counsel patients and families on ophthalmologist-prescribed therapy.

Select concentration

ATOM2 (Chia et al. 2012): ~60% reduction in myopia progression vs placebo over 2 years. Mean progression −0.49 D/yr vs −0.30 D/yr at 0.01%. LAMP 2-year data (Yam et al. 2020): 0.01% inferior to 0.05% and 0.1% on axial length control.

ATOM2 (2012): 0.01% had least side-effects with moderate efficacy; best rebound profile at cessation.

LAMP (2019–2021): 0.01% showed least AL control — may be insufficient for faster progressors.

Key References

• Chua WH et al. Atropine for the Treatment of Childhood Myopia (ATOM1). Ophthalmology 2006;113(12):2285–91.
• Chia A et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (ATOM2). Ophthalmology 2012;119(2):347–54.
• Yam JC et al. Low-Concentration Atropine for Myopia Progression (LAMP Study). Ophthalmology 2019;126(1):113–24.
• Yam JC et al. LAMP Study Year 2 Report. Ophthalmology 2020;127(7):910–19.
• IMI – Interventions Myopia Institute White Paper on Myopia Control. Invest Ophthalmol Vis Sci 2019;60(3):M106–31.